Sodium Bicarbonate for Severe Metabolic Acidemia and Acute Kidney Injury: The BICARICU-2 Randomized Clinical Trial
Primary resultResult — go to the resultAbsolute difference 0.4 95% CI −7.2 to 8.0Authors' conclusion
For patients with severe metabolic acidemia and moderate to severe acute kidney injury, intravenous sodium bicarbonate did not affect mortality.
Study context
- Population
- Adults with severe metabolic acidemia (pH ≤7.20) and moderate to severe AKI in 43 French ICUs627 analysed
- Participants
- 640 adults
- Comparison
- IV sodium bicarbonate infusion vs no sodium bicarbonate
- Bicarbonaten = 314
- Controln = 313reference
- Primary endpoint
- All-cause mortality
- Follow-up
- Day 90
Methodological detailsopen-label, multicentre
- Open-label
- Multicentre
Primary result
As reported in the abstract
Absolute difference
0.4
95% CI −7.2 to 8.0
P = 0.91
Events by treatment group
Bicarbonate vs Control
absolute difference 0.4 (95% CI −7.2 to 8.0); P = 0.91
Secondary outcomes
| Outcome | Bicarbonate | Control | Absolute difference (95% CI) | |
|---|---|---|---|---|
| Kidney replacement therapy use | 35% | 50% | −15.5 (−23.1 to −7.8) | |
| −30−20−10010Difference (linear scale) |
Day 28 and day 180 all-cause mortality
- No evidence of a group effect
Other secondary outcomes
- No evidence of a group effect
Safety
Adverse events
- No evidence of a group effect
Original publication
Sodium Bicarbonate for Severe Metabolic Acidemia and Acute Kidney Injury: The BICARICU-2 Randomized Clinical Trial. JAMA. Published 9 December 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →